tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Repare Therapeutics Signs Licensing Deal with Debiopharm
PremiumCompany AnnouncementsRepare Therapeutics Signs Licensing Deal with Debiopharm
3M ago
Closing Bell Movers: Victory Capital gains on S&P 400 inclusion
Premium
The Fly
Closing Bell Movers: Victory Capital gains on S&P 400 inclusion
3M ago
Repare Therapeutics enters licensing pact with Debiopharm for Lunresertib
Premium
The Fly
Repare Therapeutics enters licensing pact with Debiopharm for Lunresertib
3M ago
Repare Therapeutics reports Q1 EPS (71c) vs 30c last year
PremiumThe FlyRepare Therapeutics reports Q1 EPS (71c) vs 30c last year
5M ago
Repare Therapeutics expects cash to fund operations through 2027
Premium
The Fly
Repare Therapeutics expects cash to fund operations through 2027
5M ago
RPTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
RPTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
6M ago
Cathie Wood’s ARK Invest Snaps Up Tesla Stock (TSLA) amid 42% Price Drop
PremiumMarket NewsCathie Wood’s ARK Invest Snaps Up Tesla Stock (TSLA) amid 42% Price Drop
7M ago
Repare Therapeutics: Strategic Focus and Financial Stability Underpin Buy Rating
Premium
Ratings
Repare Therapeutics: Strategic Focus and Financial Stability Underpin Buy Rating
7M ago
Strategic Pipeline Focus and Financial Stability Support Buy Rating for Repare Therapeutics
Premium
Ratings
Strategic Pipeline Focus and Financial Stability Support Buy Rating for Repare Therapeutics
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100